Sickle Cell Disease: History and Discovery

Sickle cell disease has one of the most instructive histories in all of medicine — not because Western science discovered it, but because Western science arrived late. West African communities had named and described the illness for centuries before a single case reached a medical journal. When that case finally did, in a Grenadian dental student named Walter Clement Noel examined in Chicago in 1904 and published by James B. Herrick in 1910, it set off a chain of breakthroughs: the first disease ever traced to a single faulty molecule (Pauling, 1949), the first to be pinned to a single mistyped amino acid (Ingram, 1956–1957), and one of the first to reveal why a “harmful” gene survives — because in one copy it guards against malaria (Allison, 1954). This page tells that story carefully, naming who described what and when, and honoring the African knowledge that came first.

Table of Contents

  1. African Knowledge Came First
  2. Walter Clement Noel and the 1910 Herrick Report
  3. Naming the Disease and the Early Decades
  4. Pauling 1949: The First “Molecular Disease”
  5. Ingram 1956–1957: One Amino Acid
  6. The Malaria Link and Heterozygote Advantage
  7. Konotey-Ahulu and the African Lineage
  8. From Description to Treatment and Cure
  9. Research Papers and References
  10. Connections

African Knowledge Came First

It is essential to begin where the history actually begins, which is not in a Western hospital. Across West Africa, in the regions where the sickle cell gene is most common, communities recognized, named, and lived with this illness for centuries before it was documented in European or American medicine. This is not a marginal footnote — it is the foundational fact of the disease's history, and it deserves to be stated plainly: the people who carried the gene understood its hereditary, recurrent, painful character long before any microscope was turned on it.

The Ghanaian physician and human geneticist Felix Konotey-Ahulu documented several onomatopoeic names by which the hereditary syndrome was known to different peoples — among them chwechweechwe, nwiiwii, hemkom, ahotutuo, and nuidudui — names that echo the repetitive, gnawing quality of the recurrent bone and joint pain that defines the illness. These names, used by Ga, Akan, Ewe, Fante and other communities, encode real clinical observation: a condition that ran in families, returned again and again, and struck the limbs. Konotey-Ahulu's work establishes that the disease was a known and named entity in West Africa generations before 1910.

In parts of southern Nigeria, the Yoruba concept of abiku (“born to die”) and the Igbo concept of ogbanje (“one who comes and goes”) were broad spiritual frameworks used to explain children who sickened and died young and then, it was believed, were reborn into the same family. These are not simply old words for sickle cell disease — they are wider cultural and metaphysical concepts that explained several causes of recurring childhood death. But scholars studying these traditions have noted that the pattern of a child suffering repeated painful crises, swelling, and early death within one lineage maps closely onto severe sickle cell disease, and that such children were very plausibly among those described this way. Presented respectfully, as the documented worldview of these communities, the abiku/ogbanje traditions show a society grappling thoughtfully with an inherited illness it could see but not yet name biochemically.

Back to Table of Contents

Walter Clement Noel and the 1910 Herrick Report

The first description of sickle cell disease in the Western medical literature is credited to the Chicago physician James B. Herrick, and the case at its center belonged to a young man named Walter Clement Noel. Noel was a dental student from the Caribbean island of Grenada, then a British colony, who had come to study at the Chicago College of Dental Surgery, arriving in 1904. In late November and December of 1904 — not 1910 — Noel sought care at Presbyterian Hospital in Chicago for weakness, shortness of breath, and episodes of pain, the symptoms of severe anemia. It is worth fixing this date clearly: the patient was examined in 1904, but the case was not published until 1910, and the two dates are often conflated.

The crucial first observation was made not by Herrick but by his intern, Ernest E. Irons. Irons performed the peripheral blood smear and noted the strange “pear-shaped and elongated” red cells, recording his findings in careful case notes. Herrick, the attending physician, recognized the significance of what Irons had seen, followed the patient over several years, and ultimately published the landmark paper. The honest historical picture is therefore one of collaboration: Irons did the bench work and the first description of the cells; Herrick provided the clinical oversight and brought the case to the wider medical world. Modern historians have rightly worked to restore Irons's name to this story, and Noel's.

Herrick's paper, “Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia,” appeared in 1910 in the Archives of Internal Medicine. It is the description — “peculiar elongated and sickle-shaped” cells — that eventually gave the disease its name. Walter Clement Noel completed his dental training, returned to Grenada to practice, and died there in May 1916, at the age of 32, of complications consistent with his disease. He was the first patient with sickle cell disease ever described in Western medicine, and he deserves to be remembered as a person, not merely a “case.”

Back to Table of Contents

Naming the Disease and the Early Decades

Herrick described the cells but did not give the disease the name we use today. That came in 1922, when Verne R. Mason, then a resident at Johns Hopkins, used the term “sickle cell anemia” in a report published in the medical literature. The phrase stuck, and the sickle — the curved harvesting blade whose shape the deformed red cells resemble — became the permanent emblem of the disease. The earliest reports trickled in case by case; by the early 1920s only a handful had been published, and the condition was still regarded as a rare curiosity.

Two conceptual advances marked the following decades. First, researchers established that the sickling was triggered by low oxygen: in 1927 it was shown that removing oxygen from the blood of affected individuals caused the red cells to assume their characteristic sickle shape, linking the cell deformation to the conditions inside the body's small vessels. Second, the inheritance pattern was clarified. By the late 1940s, the geneticist James V. Neel demonstrated that sickle cell anemia is inherited in a Mendelian recessive fashion: people with the full disease carry two copies of the gene, while those with one copy have the milder sickle cell trait. Neel's genetic analysis, published in 1949, appeared in the same period as the molecular work described below and complemented it perfectly — the genetics and the biochemistry converged on the same conclusion at almost the same moment.

This distinction between disease and trait would prove to be one of the most important ideas in twentieth-century human biology, because it set up the central puzzle: if two copies of the gene cause a serious, often fatal illness, why is the gene so common in the populations where it appears? The answer would come from an unexpected direction — the study of malaria.

Back to Table of Contents

Pauling 1949: The First “Molecular Disease”

The single most transformative moment in the science of sickle cell disease came in 1949, from the laboratory of the chemist Linus Pauling at Caltech. Working with Harvey A. Itano, S. Jonathan Singer, and Ibert C. Wells, Pauling asked whether the defect lay in the hemoglobin molecule itself — the protein inside red cells that carries oxygen. Using a technique called electrophoresis, which separates proteins by their electrical charge, the team showed that the hemoglobin of people with sickle cell anemia moves differently from normal hemoglobin in an electric field, meaning it carries a different charge and is therefore a physically different molecule.

Their paper, “Sickle Cell Anemia, a Molecular Disease,” was published in Science on 25 November 1949. The title itself was a landmark: this was the first time any human disease had been defined at the molecular level — the first “molecular disease.” The work also elegantly explained the disease-versus-trait distinction: people with sickle cell anemia had only the abnormal hemoglobin, while those with sickle cell trait had a mixture of normal and abnormal hemoglobin, exactly as one would expect if the trait carried one copy of each gene. Biochemistry and genetics now told the same story.

It is hard to overstate what this meant for science as a whole. Pauling's result demonstrated that an inherited gene could produce a specific, identifiable change in a specific protein — that the abstract idea of a “gene” was connected, through chemistry, to a real molecule you could measure in a test tube. This insight helped launch the entire field of molecular medicine and is one reason the history of sickle cell disease is taught far beyond hematology. The next question was obvious and immediate: what, exactly, was different about the abnormal hemoglobin?

Back to Table of Contents

Ingram 1956–1957: One Amino Acid

The answer arrived a few years later and was, if anything, even more astonishing in its precision. Working at the Cavendish Laboratory in Cambridge, the biochemist Vernon M. Ingram set out to find the chemical difference between normal hemoglobin and sickle hemoglobin. Hemoglobin is a large protein built from hundreds of amino-acid building blocks; the abnormal version differed in charge, but no one knew where or how. Ingram developed an ingenious method — later nicknamed “fingerprinting” — that broke the protein into small fragments, spread them out by a combination of electrophoresis and chromatography, and compared the patterns from normal and sickle hemoglobin.

In 1956, with colleagues including John A. Hunt and Antony O. W. Stretton, and refined in 1957, Ingram pinpointed the difference to a single amino-acid substitution: at position 6 of the beta-globin chain, the amino acid glutamic acid is replaced by valine. Out of the entire hemoglobin molecule, one building block in the right place — and only one — is wrong. This was the first time a human disease was traced to a single, specific change in a single protein, the most fine-grained explanation of an illness that had ever been achieved.

The consequences of that one swap are precise and devastating. Glutamic acid carries a negative charge and likes water; valine is greasy and water-avoiding. Placing a sticky, water-fearing valine on the outside of the hemoglobin molecule creates a tiny adhesive patch. When oxygen levels fall, these patches cause sickle hemoglobin molecules to link together into long, stiff fibers that distort the soft red cell into the rigid sickle shape — the cells that block small vessels and cause the pain crises, organ damage, and anemia of the disease. Ingram's discovery thus connected a single letter of the genetic code to the suffering of patients, completing the chain from gene to molecule to cell to symptom. Together with later genetic work, it pointed to the underlying DNA mutation — a single change in the beta-globin gene — that is the root cause of the disease.

Back to Table of Contents

Running alongside the molecular story was an evolutionary mystery: why had a gene that, in double dose, causes a serious and historically often-fatal disease become so common across Africa, the Mediterranean, the Middle East, and India? Natural selection should weed out harmful genes. The resolution, one of the most celebrated findings in human genetics, came from the British physician and scientist Anthony C. Allison.

Studying populations in East Africa, Allison published in 1954 evidence that people with sickle cell trait — one copy of the gene — were protected against severe malaria, specifically Plasmodium falciparum. His paper, “Protection Afforded by Sickle-Cell Trait against Subtertian Malarial Infection,” appeared in the British Medical Journal. He observed that the geographic distribution of the sickle cell gene closely overlapped the distribution of malaria, and that children carrying the trait had fewer and milder malaria infections. The single copy of the gene that does little harm on its own gives a powerful survival edge in a malarial environment.

This is the textbook example of balanced polymorphism, or heterozygote advantage. In regions where falciparum malaria is a leading killer of children, carriers of one sickle cell gene survive malaria better than people with two normal genes, while people with two sickle cell genes suffer sickle cell disease. The gene persists at high frequency because the malaria protection it confers in carriers outweighs, at the population level, the cost it imposes on the smaller number who inherit two copies. The disease is, in a hard evolutionary sense, the price a population pays for malaria resistance — a finding that reframed sickle cell disease as a window onto how human populations adapt to infectious pressure, and that firmly locates the gene's origin in the malarial belt of the Old World.

Back to Table of Contents

Konotey-Ahulu and the African Lineage

If the molecular story belongs to Pauling and Ingram, and the evolutionary story to Allison, then the work of restoring the African dimension of sickle cell disease belongs in large part to Felix Konotey-Ahulu. A Ghanaian physician and one of the foremost clinical authorities on the disease in the twentieth century, Konotey-Ahulu spent his career studying sickle cell disease in the population where it is common, rather than as a rare imported curiosity, and insisted that African patients and African knowledge be placed at the center of the story.

In a remarkable piece of clinical genealogy, Konotey-Ahulu traced the sickle cell gene through his own extended family, with patients' names, generation by generation back to about AD 1670 — documenting the inherited illness across roughly three centuries of a single Ghanaian lineage. This work, together with his cataloguing of the indigenous onomatopoeic names discussed above, provided concrete evidence of how long and how clearly West African communities had recognized the condition. He authored the major clinical reference The Sickle Cell Disease Patient and published prolifically on the disease's management, genetics, and social dimensions over four decades.

Konotey-Ahulu's contribution is a reminder that “discovery” in medicine is often really documentation — the formal recording of something people already knew. The communities that named the illness chwechweechwe centuries ago were not waiting to be informed that it existed; what modern science added was the mechanism, the molecule, and eventually the means to treat it. A complete history of sickle cell disease holds both truths at once: the rigor of the Western laboratory tradition and the priority of African observation. Telling it any other way would be both inaccurate and unjust to the patients and communities most affected.

Back to Table of Contents

From Description to Treatment and Cure

For most of the twentieth century, understanding the disease far outpaced the ability to treat it. Care meant managing pain, transfusing blood, treating infections, and, after a landmark recognition of the danger, protecting young children from the overwhelming bacterial infections to which they are vulnerable. The first medication shown to change the disease's course was hydroxyurea, which works largely by raising levels of protective fetal hemoglobin. After the Multicenter Study of Hydroxyurea demonstrated that it reduced painful crises, hospitalizations, and acute chest syndrome, it was approved by the U.S. Food and Drug Administration for adults with sickle cell disease in 1998, and later for children.

The pace of new therapy accelerated sharply in the twenty-first century. In 2019, two further drugs were approved in the United States: voxelotor, which binds hemoglobin to keep it in its oxygen-holding shape and slow sickling, and crizanlizumab, an antibody aimed at reducing the cell-sticking that triggers pain crises. (Therapies continue to be studied, refined, and in some cases withdrawn as evidence matures, so the active drug list changes over time; patients should rely on current clinical guidance.) Allogeneic bone-marrow (stem-cell) transplantation from a matched donor had also, for decades, offered a potential cure for selected patients, though donor availability and risks limited its reach.

The most dramatic chapter opened in December 2023, when the FDA approved the first gene therapies for sickle cell disease: Casgevy (exagamglogene autotemcel), the first approved therapy to use CRISPR/Cas9 gene editing, and Lyfgenia (lovotibeglogene autotemcel), which uses a viral vector to add a modified globin gene. Both work on a patient's own blood-forming stem cells to restore healthy red-cell function. More than a century after Herrick described Noel's sickled cells, and after each link in the chain — molecule, amino acid, gene, and DNA letter — had been identified, medicine reached the point of editing the responsible gene itself. These therapies are complex, demanding, and not yet available to most of the world's patients, the majority of whom live in sub-Saharan Africa and India; the history of equitable access is still being written. But the scientific arc — from a named illness in a West African oral tradition, to the first molecular disease, to a gene-edited cure — is one of the most complete in the history of human medicine.

Back to Table of Contents

Research Papers and References

The references below combine the foundational primary papers in the history of sickle cell disease — several of which are landmarks of twentieth-century science — with curated PubMed topic-search links into the historical and ethnographic literature. Where a stable identifier is available it is given; otherwise a PubMed search link opens at the National Library of Medicine in a new tab. Historical primary sources (Herrick 1910, Mason 1922, Pauling 1949, Ingram 1956–1957, Allison 1954) are cited directly.

  1. Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Archives of Internal Medicine. 1910;6(5):517-521. — doi:10.1001/archinte.1910.00050330050003
  2. Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia, a molecular disease. Science. 1949;110(2865):543-548. — doi:10.1126/science.110.2865.543
  3. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature. 1956;178(4537):792-794. — doi:10.1038/178792a0
  4. Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature. 1957;180(4581):326-328. — doi:10.1038/180326a0
  5. Allison AC. Protection afforded by sickle-cell trait against subtertian malarial infection. British Medical Journal. 1954;1(4857):290-294. — doi:10.1136/bmj.1.4857.290
  6. Neel JV. The inheritance of sickle cell anemia. Science. 1949;110(2846):64-66. — doi:10.1126/science.110.2846.64
  7. Savitt TL, Goldberg MF. Herrick's 1910 case report of sickle cell anemia: the rest of the story. JAMA. 1989;261(2):266-271. — PubMed: Herrick's 1910 case report — the rest of the story
  8. Serjeant GR. The natural history of sickle cell disease. Cold Spring Harbor Perspectives in Medicine. 2013;3(10):a011783. — doi:10.1101/cshperspect.a011783
  9. Walter Clement Noel — first patient described with sickle cell disease (historical biography, U.S. National Library of Medicine) — PMC: Walter Clement Noel, the first described patient
  10. Konotey-Ahulu FID — West African indigenous names and the sickle-cell lineage traced to c. AD 1670 — PubMed: Konotey-Ahulu sickle cell hereditary qachoo / chwechweechwe
  11. Sickle cell disease in African traditional medicine and indigenous knowledge — PubMed: sickle cell disease Africa traditional indigenous history
  12. Mason VR. Sickle cell anemia (1922 landmark article naming the disease) — PubMed: Mason 1922 — naming of sickle cell anemia
  13. History of hydroxyurea and the Multicenter Study of Hydroxyurea (MSH) — PubMed: hydroxyurea sickle cell — MSH and history
  14. Gene therapy for sickle cell disease — CRISPR/Cas9 and lentiviral approaches (Casgevy, Lyfgenia) — PubMed: gene therapy sickle cell disease (CRISPR, gene editing)

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents